Auxilium Pharma to market Stendra for Erectile Dysfunction in the US and Canada
Vivus, Inc. has announced the signing of an agreement providing Auxilium Pharmaceuticals, Inc. the exclusive rights to market Stendra (avanafil) in the United States and Canada. The parties also simultaneously signed a Commercial Supply Agreement pursuant to which Vivus will be responsible for the manufacture and supply of Stendra to Auxilium for a mutually agreed term.
Stendra is an oral therapy approved by the FDA for the treatment of Erectile Dysfunction (ED). Under the license agreement, Vivus is eligible to receive up to $300 million based on certain regulatory and sales milestones, including an upfront licensing fee of $30 million and a $15 million payment contingent upon a potential label amendment regarding onset-of-action, in addition to royalties on product sales.
Auxilium expects to begin its commercial launch of Stendra by the end of 2013, first with shipments of Stendra in December 2013, followed by promotional activities in early January 2014 with its PRIMERA sales force.
Related news and insights
Zai Lab Limited and its partner Entasis Therapeutics Holdings Inc. announced topline results from the ATTACK trial, a global Phase III registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.
Atea Pharmaceuticals, Inc. reported that the global Phase II MOONSONG trial evaluating AT 527 in the outpatient setting did not meet the primary endpoint of reduction from baseline in the amount of SARS-CoV-2 virus in patients with mild or moderate COVID-19 compared to placebo in the overall study population, of which approximately two thirds of patients were low-risk with mild symptoms.